ASPREE participants in the US and Australia have been invited to participate in a longitudinal, observational follow-up ASPREE-XT (eXTension) study to determine:
1. Long term effects of daily aspirin treatment on the incidence of cancer, metastases and cancer-associated mortality.
2. Long term effects of daily aspirin treatment on the ASPREE secondary outcomes including cognitive decline and frailty.
3. Effects of aspirin cessation of the ASPREE cardiovascular outcomes.
4. Demographic, comorbid, genomic and environmental factors that contribute to the maintenance of cognition and other aspects of healthy aging in a highly phenotyped cohort of older adults.
Objectives of the ASPREE-XT (eXTension) study
The primary objective is to determine whether there are long-lasting effects of an average of 4.7 years of treatment with daily low-dose aspirin on the key outcome measures of cancer, metastases and cancer mortality.
An additional objective is to study the impact of demographic, comorbid, environmental and genomic factors on the maintenance of cognition and other aspects of health that may affect older people. This objective will enable insights that may improve advice available to US and Australian adults to maintain health during their later years.